US Patent 9388144 Radiolabeled prostate specific membrane antigen inhibitors
Patent 9388144 was granted and assigned to Molecular Insight Pharmaceuticals, Inc. on July, 2016 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 9388144 Radiolabeled prostate specific membrane antigen inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.